Metformina + Vildagliptina Sandoz (Metformin Hydrochloride, Vildagliptin)

Metformina + Vildagliptina is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

• Type 2 diabetes mellitus: improves overall glycaemic control and reduces HbA1c when added to diet, exercise and other therapies.
• Adjunct to metformin monotherapy: provides additional glucose‑lowering effect in patients not achieving targets with metformin alone.
• Combination therapy with other oral agents: offers a complementary mechanism to sulfonylureas, SGLT2 inhibitors or insulin, helping to achieve tighter glucose control.

• Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Vildagliptin inhibits the dipeptidyl‑peptidase‑4 (DPP‑4) enzyme, prolonging the activity of incretin hormones (GLP‑1 and GIP). This dual action increases glucose‑dependent insulin secretion, suppresses glucagon release, and reduces post‑prandial glucose excursions.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
• Headache: mild to moderate intensity.
• Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic complication associated with metformin.
• Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain and elevated enzymes.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: abnormal liver enzymes or hepatic failure.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal function assessment: ensure adequate creatinine clearance before prescribing.
• Hepatic function monitoring: check liver enzymes periodically.
• Lactic acidosis risk: avoid in patients with severe infection, hypoxia, or dehydration.
• Caution in elderly: dose adjustments may be needed due to reduced renal reserve.
• Concomitant antidiabetic agents: monitor for additive hypoglycaemic effect.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformina + Vildagliptina may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Iodinated contrast agents: can precipitate acute renal failure, increasing metformin accumulation.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise vildagliptin plasma levels.
• Cimetidine or trimethoprim: can reduce metformin clearance, heightening lactic acidosis risk.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal function and alter metformin excretion.
• Beta‑blockers: can mask hypoglycaemia symptoms.
• NSAIDs: may impair renal perfusion, necessitating renal function checks.